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Abstract
Epidermal growth factor receptor (EGFR or HER-1) and its analog c-erbB-2 (HER-2) are protein tyrosine kinases correlated
with prognosis and response to therapy in a variety of human cancers. KRAS mediates the transduction of signals between
EGFR and the nucleus, and its mutation has been identified as a predictor of resistance to anti-EGFR drugs. In human
oncology, the importance of the EGFR/HER-2/KRAS signalling pathway in gastric cancer is well established, and HER-2
testing is required before initiating therapy. Conversely, this pathway has never been investigated in canine gastric tumours.
A total of 19 canine gastric epithelial neoplasms (5 adenomas and 14 carcinomas) were retrospectively evaluated for EGFR/
HER-2 immunohistochemical expression and KRAS mutational status. Five (35.7%) carcinomas were classified as intestinal-
type and 9 (64.3%) as diffuse-type. EGFR was overexpressed ($1+) in 8 (42.1%) cases and HER-2 (3+) in 11 (57.9%) cases,
regardless of tumour location or biological behaviour. The percentage of EGFR-positive tumours was significantly higher in
the intestinal-type (80%) than in the diffuse-type (11.1%, p = 0.023). KRAS gene was wild type in 18 cases, whereas one
mucinous carcinoma harboured a point mutation at codon 12 (G12R). EGFR and HER-2 may be promising prognostic and
therapeutic targets in canine gastric epithelial neoplasms. The potential presence of KRAS mutation should be taken into
account as a possible mechanism of drug resistance. Further studies are necessary to evaluate the role of dog as a model for
human gastric cancer.
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Introduction
Gastric tumours are rare in dogs, representing less than 1% of
all canine malignancies [1,2]; 70–80% are epithelial adenocarci-
nomas [1]. As in humans, canine gastric carcinoma is more
prevalent in males and is usually fatal [2–5]. Gastric adenomas are
mainly incidental findings, although they may undergo malignant
transformation [1].
In humans, gastric and gastro-oesophageal junction (GEJ)
adenocarcinomas are a major cause of cancer morbidity and
mortality worldwide [6]. Although complete surgical resection is
the mainstay of treatment for non-metastatic diseases, many
patients are not diagnosed until their disease is either locally
advanced or metastatic and therefore unresectable [6]. The
prognosis in advanced stages is very poor [7].
One of the most significant innovative targets in human cancer
is the HER family. The members of this family, EGFR, c-erbB-2,
c-erbB-3 and c-erbB-4 (also known as HER-1, HER-2, HER-3
and HER-4, respectively) are normally located on cell membranes
and consist of an extracellular ligand-binding domain and an
intracellular domain with tyrosine kinase activity [8].The EGF
signalling pathway has been studied in human cancer patients with
particular attention paid to EGFR, HER-2 and their activating
ligands as the deregulation of these has been shown to play an
important role in tumour initiation, progression and metastasis
[7,8]. Aberrant HER-2 expression or function has been implicated
in gastric carcinogenesis and in other tumor types, including
breast, ovarian, salivary gland, prostate and lung cancers [9].
Trastuzumab, a recombinant humanised IgG1k monoclonal
antibody directed against the HER-2 extracellular domain, has
shown a survival advantage in patients with metastatic HER-2-
overexpressing gastric cancer [7–10], providing significant benefits
in terms of response rate, median progression-free survival and
overall survival [11]. Currently, trastuzumab in combination with
chemotherapy is considered the standard treatment for patients
with HER-2-positive advanced gastric cancer, and immunohisto-
chemistry is the primary HER-2 testing method: a score of 3+
confirms eligibility for trastuzumab therapy, whereas a 1+ score
indicates no overexpression. The interpretation of tumours scoring
2+ is open to debate, and FISH has been proposed to confirm
HER-2 overexpression in such cases [7–12].
EGFR overexpression in primary gastric carcinomas and/or
metastases has also been reported and is linked to a poor prognosis
[13–15]. An increasing interest has been shown in developing
immunohistochemistry-based screening methods to select patients
who are eligible for treatment with cetuximab, an anti-EGFR
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monoclonal antibody that has proven effective in advanced
colorectal cancer [15,16].
Signal transduction between HER receptors and the nucleus is
mediated by a small protein encoded by the KRAS gene [17]. In
human oncology, the importance of the EGFR/HER-2/KRAS
signalling pathway in gastric cancer is well established. KRAS
mutations activate RAS proteins that continuously stimulate the
signalling pathways in the absence of upstream stimulation of
EGFR (constitutive activation). Consequently, tumours bearing a
KRAS mutation are less likely to respond to anti-EGFR drugs [17].
In veterinary medicine, EGFR protein expression has been
detected in numerous tumour types, including canine mammary
tumours, primary brain tumours, nasal carcinomas, lung carcino-
mas and osteosarcomas [18–22]. HER-2 overexpression is
reported in 19% to 35% of canine mammary neoplasms [23–
25]. In a recent comparison study, Singer et al. studied canine
EGFR and HER-2 expression and biology using mammary cancer
cell lines, observing a substantial similarity between human and
canine EGFR and HER-2 tumour-associated antigens. The
antigens were recognised by trastuzumab and cetuximab antibod-
ies, leading to growth inhibition in canine mammary cancer cell
lines. This finding supports the development of novel targeted
therapies and adjuvant strategies for the treatment of EGFR/
HER-2-expressing canine cancers [26]. Conversely, the EGFR/
HER-2/KRAS pathway has never been investigated in canine
gastric cancer.
The aim of the present study was to evaluate EGFR and HER-2
immunohistochemical expression and KRAS mutational status in a
series of canine gastric tumours. More in-depth knowledge of the
role of these molecular pathways could provide new insights into
the treatment of canine gastric tumours and into the evaluation of
dogs as a comparative model for human cancers.
Materials and Methods
Ethics Statement
This study is a retrospective investigation carried out on
archived tissue samples from dogs with gastric tumours. As the
research did not influence any therapeutic decision in human
subjects, approval by an Ethics Committee was not required.
However, all diagnostic and therapeutic procedures were per-
formed in accordance with the Public Health Service Policy on
Humane Care and Use of Laboratory Animals.
All the examined samples were collected for diagnostic purposes
as part of routine standard care. Owners gave informed consent to
the use of clinical data and stored biological samples for teaching
and research purposes.
Criteria for Case Inclusion
Formalin-fixed and paraffin-embedded (FFPE) tissue samples
from dogs with a histological diagnosis of benign or malignant
epithelial gastric tumours were retrieved from the archives of the
Department of Veterinary Medical Sciences, University of
Bologna, Italy, the Veterinary Oncology Center, Sasso Marconi,
Italy, and the Faculty of Veterinary Medicine, University of
Ghent, Belgium. Only primary benign and malignant epithelial
gastric tumours, as confirmed by clinical and/or post-mortem
findings, were used. Endoscopic biopsies and surgical or post-
mortem samples were also included. Reference haematoxylin-
eosin stained sections were reviewed by an experienced veterinary
pathologist (GB) to confirm the original diagnosis and to
standardise the pathological classification according to WHO
guidelines for the classification of gastrointestinal tumours of
domestic animals [27]. Tumours were divided into two main
histological groups for statistical purposes: intestinal-type (com-
prising tubular/papillary adenocarcinomas) and diffuse-type
(comprising signet ring/mucinous carcinomas and anaplastic
carcinomas) [28]. Only tissue sections containing more than
50% of tumour cells were included in the study. If available,
tumour stage according to the TNM classification proposed by the
American Joint Committee on Cancer was recorded [29]. EGFR/
HER-2 expression was also investigated in 10 samples of normal
canine gastric mucosa.
EGFR and HER-2 Immunohistochemistry
EGFR and HER-2 expression was detected by immunohisto-
chemistry (IHC) using commercial anti-human antibodies whose
reactivity in canine tissues has previously been validated [19–30].
Four-micrometer-thick FFPE tissue sections were de-waxed and
rehydrated. Endogenous peroxidase activity was blocked by
incubation for 30 min with 3% hydrogen peroxide in distilled
water. For EGFR, antigen retrieval was obtained by incubating
sections in a 0.05% protease XIV (from Streptomyces griseus,
P5147-1G, Sigma Aldrich, MO, USA) solution (pH 7.5) for
15 min at 37uC. Subsequently, sections were incubated for 60 min
at 37uC in a humid chamber with the primary antibody (EGFR
Ab-10, clone 111.6; mouse monoclonal; NeoMarkers, Fremont,
CA, USA) diluted 1:100 in phosphate buffered saline (PBS;
pH 7.4, 0.01 M). Sections were incubated with a high sensitivity
detection kit (EnVision Plus-HRP, Dako, Glostrup, Denmark),
according to the manufacturer’s instructions.
For HER-2, antigen was retrieved with citrate buffer (2.1 g
citric acid monohydrate/litre distilled water), pH 6.0, and heated
for two 5-min periods in a microwave oven at 750 W. Sections
were treated with a protein-blocking solution (Protein Block
Serum-Free, Dako) for 20 min. Tissue sections were then
incubated overnight at 4uC with the primary antibody (anti c-
erb-B2 oncoprotein; rabbit polyclonal, Dako) diluted 1:50 in a
solution of 1% bovine serum albumin and PBS. Sites of primary
antibody binding were identified using a commercial streptavidin-
biotin-peroxidase kit (LSAB, Dako) and diaminobenzidine was
used as chromogen (0.04% for 10 min at room temperature).
Sections were then counterstained with Papanicolaou’s hema-
toxylin. Sections of canine mammary carcinomas known to
express the tested antigens were used as positive controls. Negative
controls were obtained by substituting the primary antibody with
an unrelated serum.
The immunohistochemical expression of EGFR was graded as
follows: 0, no staining observed or membrane staining in ,1%
neoplastic cells; 1+, weak complete or incomplete membrane
staining in .1% neoplastic cells; 2+, moderate complete or
incomplete membrane staining in .1% neoplastic cells; 3+, strong
complete or incomplete membrane staining in .1% neoplastic
cells. Cases with an EGFR score $1+ were considered positive
[31]. HER-2 was evaluated according to the criteria proposed by
Hofmann et al [32] for human gastric cancer. HER-2 positivity
(3+ IHC reaction) was defined as strong, complete or basolateral
membranous immunoreactivity in at least 10% of tumour cells. In
biopsies, a cluster (approximately five or more) of positively stained
cells was considered positive [12]. EGFR and HER-2 expression
was further evaluated in biopsy samples of gastric mucosa from ten
dogs submitted to biopsy for tumour-unrelated causes.
DNA Extraction and KRAS Gene Analysis
FFPE block-derived sections from gastric lesions were reviewed
for quality and cellular content. DNA was extracted from 5-mM
FFPE sections. Cells were lysed in 50 mM KCl, 10 mM Tris-HCl
pH 8.0, 2.5 mM MgCl2 and Tween-20 0.45%, with the addition
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of Proteinase K at a concentration of 1.25 mg/ml, overnight at
56uC. Proteinase K was inactivated at 95uC for 10 minutes after
which samples were centrifuged twice to eliminate debris.
Supernatant was assessed for DNA quality and quantity by
Nanodrop (Celbio, Milan, Italy) and was then submitted to PCR
amplification.
Exon 2 of canine KRAS gene was amplified by PCR using the
following primers: forward 59-CTG CACTGAATTTTCT-
GAAGCA-39 and reverse 59 AAA ATG GGC CTG CAC AAA
T9. PCR products were purified using the Minielute PCR
purification kit (Qiagen, Hilden, Germany) and then submitted
to sequencing using the BigDye Terminator 3.1 Reaction Cycle
Sequencing kit (Applied Biosystems, Foster City, CA, USA).
Sequence reactions were purified using the DyeEx 2.0 Spin kit
(Qiagen) and separated by capillary electrophoresis with laser-
induced fluorescence detection (3130 Genetic Analyzer, Applied
Biosystems). Sequencing products were analysed in comparison
with the wild type sequence of the gene.
Statistical Analysis
The association between EGFR/HER-2 expression (positive/
negative) and clinical pathological parameters (tumour stage,
location, malignancy and histotype) were tested for significance
with Fisher’s exact test. Significance was set at p,0.05. Tests were
carried out with GraphPad Prism 5.0 (GraphPad Software, San
Diego, CA, USA).
Results
Nineteen samples were collected (7 endoscopic biopsies, 8
surgical samples and 4 post-mortem samples). There were five
benign tumours (26.3%; 1 tubular adenoma, 1 papillary adenoma,
and 3 tubulopapillary adenomas) and 14 gastric carcinomas
(73.7%; 1 in situ carcinoma, 2 tubular adenocarcinomas, 1
papillary adenocarcinoma, 1 tubulopapillary adenocarcinoma, 8
mucinous/signet ring cell carcinomas and 1 undifferentiated
carcinoma). There were 5 intestinal-type (35.7%) and 9 diffuse
type carcinomas (64.3%) according to Lauren’s classification [28].
Tumours were located in the cardia (n = 1; 5.9%), gastric fundus
(n = 2; 10.5%), lesser curvature (n = 6; 31.6%) and pyloric antrum
(n= 8; 42.1%). In two (10.5%) cases, tumour location was
unavailable. No statistical correlation was found between tumour
location and histological type. Grossly, diffuse-type tumours most
often appeared as a diffuse thickening of gastric mucosa (linitis
plastica), while intestinal-type tumours frequently had the appear-
ance of polypoid-like lesions or mucosal plaques with ulceration.
Among malignant tumours, 4 (40%) were stage I, 2 (20%) were
stage III and 4 (40%) were stage IV. The mean age of the affected
dogs was 10.8 years for adenomas and 8.8 for carcinomas (range
3–16 years); 12 dogs were males (63.2%) and 7 were females
(36.8%). There were 3 Boxers, 2 Shih-tzus, 5 crossbreeds, and 9
dogs of other breeds. Animal details are summarised in Table 1.
EGFR and HER-2 Expression
The EGFR protein was expressed in 8 (42.1%) out of 19
samples. Five (26.3%) cases were scored as 1+, 1 (5.3%) case was
scored as 2+ and 2 (15.8%) cases were scored as 3+ (Figure 1a,b).
No differences were observed in EGFR expression on the basis of
tumour stage, location or malignancy. The percentage of EGFR-
positive lesions was significantly higher among intestinal-type
(80%) than diffuse-type (11.1%, p= 0.023) tumors (Table 2).
Eleven (57.9%) tumours were considered HER-2 positive (3+). In
the remaining cases (n = 7; 36.9%), HER-2 expression was
classified as 2+ (Figure 1c,d). In one dog (case 19), HER-2 analysis
was not possible because of tissue exhaustion. No statistically
significant differences in HER-2 positivity were observed on the
basis of clinical pathological parameters (Table 2). In adenomas,
HER-2 staining was more intense in dysplastic areas.
EGFR/HER-2 expression was not detected in the 10 samples of
normal gastric mucosa, with the exception of scattered foci of weak
basolateral positivity (Figure 1e,f).
KRAS Gene Analysis
All five adenomas showed a wild type KRAS gene status. Of the
14 carcinomas, 13 were KRAS wild type and one was mutated. The
identified mutation was a G to C transversion at the first position
of codon 12 of the gene (GGT R CGT (G12R)), which induces
the substitution of a glycine with an arginine. The mutation was
found in stage IV mucinous/signet-ring cell carcinoma (Figure 2).
Discussion
HER-2 and EGFR are transmembrane tyrosine kinases that can
promote tumour genesis and progression. Expression of HER-2
and EGFR appear to be closely related, and one or both proteins
are frequently overexpressed in gastric epithelial cancer cells [8].
In recent years, new developments in cancer biology have led to
the emergence of novel molecular-targeted therapeutics. These
drugs act selectively on cancer cells at a molecular, biochemical
and genetic level, specifically targeting abnormal cells, with
minimal effects on the function of normal cells [8]. As in humans,
the prognosis of canine gastric cancer is very poor and currently
available therapeutic aids fail to significantly prolong survival. The
need for new treatment options thus encourages in-depth studies
on the role of these molecules as potential therapeutic targets in
veterinary medicine as well. Additionally, strong similarities have
been observed between human and canine gastric cancer with
regard to clinical presentation and histopathological features,
which indicates the dog as a potential comparative model for
human gastric cancer.
Our retrospective study was conducted on 19 cases of canine
gastric epithelial tumours, the small number of cases possibly
constituting a limitation.Data on clinical stage were not available
in six dogs (nos. 1, 2, 3, 4, 5 and 19). A 1.7:1 male to female ratio
was observed, confirming the male predisposition previously
reported by other authors [2–5]. Additionally, our data support
the preferential localisation of these tumours to the pyloric antrum
and lesser curvature [33–35].
Overall, both receptors were expressed in a high percentage of
cases (EGFR: 42%, HER-2: 61%). All HER-2 negative cases were
also negative for EGFR expression, whereas a subset of EGFR-
negative tumours was found among HER-2 positive tumours.
Immunohistochemical expression was membranous, complete or
basolateral. EGFR positivity among tumors was extremely
heterogeneous, whereas we did not observe major intra-tumour
differences in HER-2 expression.
In humans, HER-2 immunohistochemical expression varies
according to tumour location, with a higher rate of HER-2
positivity in GEJ tumours compared to those located in the gastric
body (34% vs 20%) [11].The single most important factor for the
development of these tumours is the mucosal irritation caused by
chronic GE reflux. In such cases squamous epithelium is eroded
and replaced by columnar epithelium, either by intestinal
metaplasia or by the extension of columnar epithelium from the
stomach (Barrett’s oesophagus) [35,36].
HER-2 expression in humans also differs significantly on the
basis of histological subtype. Intestinal-type cancers usually exhibit
higher rates of HER-2 positivity compared to diffuse-type tumors
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(34% vs 6%)9. No clear correlation has been found between EGFR
expression and tumour location or histotype.
Among the cases in this study, only one tumour was located in
the GEJ (HER-2, 2+); the remaining lesions were almost equally
distributed between the gastric fundus and the pyloric antrum,
with no significant difference in receptor expression. Conversely, a
higher percentage of intestinal-type than diffuse-type carcinomas
were positive for both markers. However, this difference was only
statistically significant for EGFR.
In human gastric cancer, HER-2 is involved in the development
of relatively early-stage carcinogenesis [12]. Additionally, although
the majority of studies conducted in human medicine link the
overexpression of HER-2 to adverse prognosis [12], a small
number have not found any a correlation with the biological
behaviour of the tumour [37]. Likewise, EGFR expression has
been associated with increased tumour aggressiveness [15]. Given
the retrospective nature of this study, it was not possible to trace
the clinical follow-up of the majority of cases. Nevertheless, some
indication about tumour biological behaviour can be inferred from
Figure 1. EGFR and HER-2 immunohistochemistry of canine
samples. (A). Dog, stomach. Signet ring cell carcinoma (case No. 15).
EGFR immunohistochemistry. Faint and partial membrane labelling of
the neoplastic cells (1+). Haematoxylin counterstain. 200x. (B) Dog,
stomach. Papillary adenoma (case No. 2). EGFR immunohistochemistry.
Strong and complete membrane labeling of the neoplastic cells (3+).
Haematoxylin counterstain. 100x. (C) Dog, stomach. Tubulopapillary
adenoma (case No. 4). HER-2 immunohistochemistry. Moderate
basolateral membrane labeling of the neoplastic cells (2+). Haematox-
ylin counterstain. 200x. (D) Dog, stomach. In situ tubulopapillary
carcinoma (case No. 6). HER-2 immunohistochemistry. Strong and
complete membrane labeling of the neoplastic cells (3+). Haematoxylin
counterstain. 200x. (E) Dog, stomach, fundus. EGFR immunohistochem-
istry. Negative labeling of the mucosal epithelium. Faint granular
cytoplasmic positivity of the parietal cells. Haematoxylin counterstain.
200x. (F) Dog, stomach, pyloric antrum. HER-2 immunohistochemistry.
Scattered foci of faint basolateral positivity. Haematoxylin counterstain.
200x.
doi:10.1371/journal.pone.0085388.g001
Table 2. Association between EGFR/HER-2 status and clinical
pathological parameters in 19 canine gastric epithelial
neoplasms.
Parameter
EGFR $1+
(n=8) P
HER-2 3+
(n=11) P
Sex ns ns
Male 4/12 6/11
Female 4/7 5/7
Age, years ns ns
,10 years 2/9 3/9
.10 years 6/10 8/9
Localisation ns ns
Gastric fundus 2/6 4/7
Pyloric antrum 4/8 6/8
Malignancy ns ns
Adenomas 3/5 3/5
Carcinomas 5/14 8/13
Histotype 0.023 ns
Intestinal type 4/5 4/5
Diffuse type 1/9 4/8
Stage IV ns ns
Yes 3/4 4/4
No 1/6 3/6
doi:10.1371/journal.pone.0085388.t002
Figure 2. KRAS analysis. Mutation analysis performed by direct
sequencing on wild type (A) and mutated (B) samples. Arrows indicate
the point mutation.
doi:10.1371/journal.pone.0085388.g002
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IHC expression in gastric mucosa samples from controls compared
to those from adenomas and carcinomas.
Neither receptor was expressed in non-neoplastic gastric
mucosa, indicating their possible involvement in carcinogenesis.
Additionally, in benign tumours, HER-2 was more intensely
expressed in the focal areas of dysplasia, suggesting its potential
relevance in premalignant lesions. However, as no appreciable
differences in marker expression were observed between adenomas
and carcinomas and between locally advanced and metastatic
cancer, a correlation with tumour biological behaviour would
seem unlikely.
In human oncology it has been observed that the KRAS gene is
affected by a limited number of mutations, more than 90%
involving codons 12, 13 and 61 (exons 2 and 3). These mutations
are associated with the constitutive activation of the gene and are
considered responsible for resistance to treatment with anti-EGFR
monoclonal antibodies [38].
In gastric carcinomas, the reported frequency of KRAS point
mutations is between 8% and 10% [39,40]. Although KRAS
mutations represent a prognostic factor for colorectal and lung
cancer, their correlation with the biological behaviour of gastric
tumours is still poorly defined [38–40].
The nucleotide sequence of the canine KRAS gene is very
similar to that of the human one, and the resulting amino acidic
sequence is identical41. Kraegel and coworkers analysed KRAS
activation in a subset of canine non-small cell lung cancers: despite
the wide disparity in the incidence of non-small cell lung cancer
between dogs and humans, the frequency of KRAS point
mutation was similar. Although species-specific factors may be
responsible for mutations, exposure to common environmental
carcinogens may account for some of the identified similarities in
KRAS activation [41].
Mutation analysis of KRAS performed on our samples showed
the presence of a single mutation at codon 12. This mutation is
among the most frequently detected in humans and determines the
substitution of a glycine (the only amino acid without a side-chain)
by an amino acid with a side-chain (arginine), thus leading to a
geometric alteration of the protein. This results in a lack of GTP
hydrolysis which keeps KRAS in a permanently activated state
[42]. The mutation was found in a mucinous carcinoma of the
gastric fundus characterised by a massive infiltration of adjacent
structures and regional lymph node metastases. Unfortunately, no
information was available on the clinical course of the case, a 10-
year-old male boxer. The potential presence of KRAS mutation in
dogs should be taken into account when considering to use of
targeted drugs against the HER pathway as it could represent a
mechanism of resistance [43].
In conclusion, the present study revealed a high expression of
EGFR and HER-2 in canine gastric epithelial tumours, which
suggests a role of these receptors in carcinogenesis, especially when
compared to the constant negativity of normal gastric mucosa.
Additionally, there was a significantly higher percentage of EGFR-
positive cases among intestinal-type carcinomas. Unlike humans,
however, we did not observe a relationship between marker
expression and anatomical location or the biological behaviour of
tumours. Finally, a codon 12 mutation in the KRAS gene was
identified, equivalent to those found in human gastric carcinomas,
suggesting that this altered pathway may also exert a role in the
pathogenesis of gastric cancer in dogs.
The potential relevance of these molecules as prognostic and
predictive markers indicates the need for further studies on larger
case series involving the use, in parallel, of in situ hybridisation and
immunohistochemistry.
Conclusions
The pathological and behavioural similarities between many
spontaneous canine and human tumours make logical to extend
investigations into molecular oncogenesis to dogs. Therapeutic
targeting of EGFR and HER-2 could be a promising line of
research in canine gastric cancer. Further studies are needed to
evaluate the role of the dog as a model for human gastric cancer.
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